Last Updated: November 16, 2026

Investigational Drug Information for PF-05221304

« Back to Dashboard


What is the development status for investigational drug PF-05221304?

PF-05221304 is an investigational drug.

There have been 11 clinical trials for PF-05221304. The most recent clinical trial was a Phase 2 trial, which was initiated on August 22nd 2017.

The most common disease conditions in clinical trials are Liver Diseases, Fatty Liver, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Pfizer, Columbia University, and Henry N. Ginsberg.

There are one hundred and eleven US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for PF-05221304
TitleSponsorPhase
Effects of ACC Inhibitor on Lipid and Lipoprotein MetabolismPfizerPhase 1
Effects of ACC Inhibitor on Lipid and Lipoprotein MetabolismColumbia UniversityPhase 1
Effects of ACC Inhibitor on Lipid and Lipoprotein MetabolismHenry N. GinsbergPhase 1

See all PF-05221304 clinical trials

Clinical Trial Summary for PF-05221304

Top disease conditions for PF-05221304
Top clinical trial sponsors for PF-05221304

See all PF-05221304 clinical trials

US Patents for PF-05221304

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-05221304 ⤷  Start Trial N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors Pfizer Corp SRL ⤷  Start Trial
PF-05221304 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-05221304 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-05221304 ⤷  Start Trial N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors Pfizer Corp SRL ⤷  Start Trial
PF-05221304 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Corp SRL ⤷  Start Trial
PF-05221304 ⤷  Start Trial BCKDK inhibitors Pfizer Corp SRL ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-05221304

Drugname Country Document Number Estimated Expiration Related US Patent
PF-05221304 Canada CA2811033 2030-09-30 ⤷  Start Trial
PF-05221304 Cyprus CY1118016 2030-09-30 ⤷  Start Trial
PF-05221304 Denmark DK2621493 2030-09-30 ⤷  Start Trial
PF-05221304 European Patent Office EP2621493 2030-09-30 ⤷  Start Trial
PF-05221304 Spain ES2602111 2030-09-30 ⤷  Start Trial
PF-05221304 Croatia HRP20161178 2030-09-30 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

PF-05221304 Development Update and Market Projection

Last updated: September 3, 2026

PF-05221304 is an oral, liver-directed acetyl-CoA carboxylase (ACC) inhibitor developed by Pfizer for nonalcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH). Clinical studies showed meaningful reductions in hepatic fat, but the program faced the class risk of increased triglycerides and LDL cholesterol. PF-05221304 is not an FDA-approved medicine, has no Orange Book listing, and does not appear to be an active Pfizer commercial-stage asset. Its standalone commercial outlook is therefore limited unless Pfizer or a partner restarts development.

What is PF-05221304 and how does it work?

PF-05221304 inhibits ACC1 and ACC2, enzymes involved in fatty-acid synthesis and oxidation. The intended effect is to reduce de novo lipogenesis, lower liver fat, and improve steatohepatitis.

Attribute PF-05221304
Developer Pfizer
Drug class Liver-directed ACC inhibitor
Primary target Acetyl-CoA carboxylase 1 and 2
Intended indication NASH/MASH with liver fibrosis
Administration Oral
FDA approval None
Biologic or small molecule Small molecule
Biosimilar exposure None
Orange Book status No listed product
Public clinical stage Phase 2 evidence
Current commercial status No disclosed launch program

ACC inhibition is biologically attractive because excess hepatic lipogenesis contributes to steatosis and inflammation. The development challenge is systemic lipid disruption. ACC inhibition can increase circulating triglycerides and LDL cholesterol, requiring lipid-lowering treatment or careful patient selection.

What clinical development did PF-05221304 complete?

Pfizer evaluated PF-05221304 in early and mid-stage studies involving patients with fatty liver disease and NASH. The central clinical signal was a reduction in liver fat measured by magnetic resonance imaging-based methods.

A Pfizer-sponsored Phase 2 study evaluated PF-05221304 in participants with NASH. The clinical program examined multiple dose levels and assessed liver fat, liver enzymes, lipids, and safety outcomes. Public trial records identify PF-05221304 as an investigational treatment rather than an approved or registration-stage product. [1]

Clinical development timeline

Period Development event
Pre-2020 Pfizer advances PF-05221304 as a liver-directed ACC inhibitor
2020-2021 Phase 2 studies evaluate hepatic fat reduction and metabolic safety
2021 onward Public development visibility declines
2023-2024 Pfizer pipeline disclosures do not identify PF-05221304 as a major active late-stage program
Current status No FDA filing, approval, commercial launch, or disclosed pivotal program

Available clinical evidence supports pharmacologic activity, but it does not establish fibrosis improvement, prevention of cirrhosis, or a regulatory path to approval.

How effective was PF-05221304 in NASH or MASH?

PF-05221304 reduced hepatic fat in clinical studies. The effect was directionally consistent with the mechanism and with results seen for other ACC inhibitors. Improvements in liver enzymes and steatosis were reported, but the most important regulatory endpoint in MASH is usually fibrosis improvement without worsening of steatohepatitis, or resolution of steatohepatitis with no worsening of fibrosis.

The publicly available PF-05221304 record does not establish a confirmed histology-based registration result. That distinction is material. A large reduction in MRI-measured liver fat can support proof of mechanism, but it does not guarantee approval.

Principal efficacy strengths

  • Oral dosing.
  • Direct reduction of hepatic de novo lipogenesis.
  • Demonstrated reduction in liver fat.
  • Potential combination use with statins, incretin therapies, or other MASH agents.

Principal development weaknesses

  • No established fibrosis outcome.
  • Limited late-stage evidence.
  • Class-related triglyceride and LDL increases.
  • Potential need for combination lipid management.
  • Strong competition from approved and late-stage MASH therapies.

What safety issues affected PF-05221304 development?

The main safety and commercial concern is dyslipidemia. ACC inhibition can produce increases in triglycerides and LDL cholesterol, which may offset some of the cardiometabolic benefit expected from reducing liver fat.

Pfizer tested PF-05221304 with lipid-management strategies, including statin treatment in related clinical development. This approach could improve the benefit-risk profile, but it also adds treatment complexity and makes the drug less attractive as a simple monotherapy.

The relevant safety questions for any restart would include:

  1. Whether triglyceride increases are dose-dependent.
  2. Whether LDL elevations are fully controlled with statins.
  3. Whether lipid changes translate into cardiovascular risk.
  4. Whether patients with advanced fibrosis tolerate long-term treatment.
  5. Whether combination therapy improves fibrosis outcomes without cumulative toxicity.

What is the FDA regulatory status of PF-05221304?

PF-05221304 has no FDA approval, no approved label, and no publicly identified New Drug Application. It has not received an FDA Complete Response Letter because no public approval application is associated with the compound.

FDA and regulatory item Status
Investigational New Drug application Clinical development implied; public filing details unavailable
Breakthrough Therapy designation No public designation identified
Fast Track designation No public designation identified
New Drug Application None publicly identified
FDA approval None
Approved indication None
REMS None
Commercial label None

The approval of resmetirom, marketed as Rezdiffra, changed the competitive standard for MASH drugs. The FDA approved resmetirom in March 2024 for adults with noncirrhotic NASH with moderate-to-advanced liver fibrosis, in conjunction with diet and exercise. [2] PF-05221304 would now need to demonstrate a clinically differentiated profile against an approved therapy rather than compete only with investigational drugs.

What patents protect PF-05221304?

PF-05221304 is a Pfizer development code, not a patent identifier. Pfizer likely pursued protection through compound, pharmaceutical composition, therapeutic-use, and manufacturing patent families. The public drug code alone does not establish the complete patent estate or confirmed expiry dates.

Because PF-05221304 has no approved product, there is no FDA Orange Book patent listing. The absence of an Orange Book listing does not mean the compound lacks patent protection. It means that no approved drug product is available for FDA listing under the Orange Book framework.

Likely patent categories

Patent category Commercial purpose
Composition of matter Protects the PF-05221304 chemical entity and related compounds
Pharmaceutical composition Protects dosage forms and excipient combinations
Method of treatment Covers treatment of NASH, fatty liver disease, dyslipidemia, or fibrosis
Combination therapy May cover use with statins or other metabolic agents
Manufacturing process Protects synthesis, intermediates, crystallinity, or purification
Selection or formulation claims May protect particular doses, salts, polymorphs, or delivery characteristics

No confirmed Orange Book expiry date or publicly validated PF-05221304 patent term should be used in a launch model. Any future restart would depend on the surviving patent family, patent-term adjustment, patent-term extension eligibility, and the scope of claims that remain enforceable.

When would PF-05221304 lose exclusivity?

PF-05221304 has no approved exclusivity period because it has no approved indication. FDA regulatory exclusivities such as five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, and seven-year orphan-drug exclusivity have not been granted for this compound.

Patent exclusivity is separate from FDA exclusivity. If Pfizer obtained composition-of-matter patents, those patents could remain relevant even without approval. Their practical value depends on whether Pfizer resumes clinical development and whether the claims cover the final clinical candidate.

Exclusivity position

Exclusivity type PF-05221304 status
New chemical entity exclusivity Not started
Orphan-drug exclusivity Not identified
Pediatric exclusivity Not identified
Patent-term extension Not available without an approved product
Orange Book-listed patents None
Generic substitution Not applicable

Are there Paragraph IV challenges or patent litigation?

No publicly identified Paragraph IV litigation or ANDA challenge affects PF-05221304. Paragraph IV litigation generally requires an approved reference drug with Orange Book-listed patents. PF-05221304 has neither.

No major public patent settlement agreement, license dispute, or infringement case involving a PF-05221304 generic challenger has been identified. The absence of litigation reflects the compound’s development status rather than proof that all patent risks have expired.

Which companies compete with PF-05221304?

PF-05221304 competes with three groups: approved MASH products, late-stage metabolic therapies, and other ACC inhibitors.

Company Asset Mechanism or class Competitive position
Madrigal Pharmaceuticals Resmetirom Thyroid hormone receptor beta agonist First FDA-approved MASH therapy
Novo Nordisk Semaglutide GLP-1 receptor agonist Strong weight-loss and metabolic profile; MASH development
89bio Pegozafermin FGF21 analog Fibrosis and steatohepatitis development
Akero Therapeutics Efruxifermin FGF21 analog Advanced-stage MASH program
Viking Therapeutics VK2809 Liver-directed thyroid hormone receptor beta agonist Liver-fat and metabolic development
Gilead Sciences Firsocostat ACC inhibitor Class comparator; development challenges include lipid effects
InventisBio and others Small-molecule metabolic agents Multiple mechanisms Competitive oral-therapy pipeline

The most direct comparator is firsocostat, another ACC inhibitor. The class has shown liver-fat reduction but has struggled to translate that effect into a clean long-term clinical and regulatory profile. PF-05221304 would need either superior lipid tolerability or a combination strategy that produces fibrosis benefit.

How strong is the PF-05221304 patent estate?

The patent estate is commercially unproven rather than clearly weak. A composition-of-matter patent can provide meaningful protection, but its value falls sharply when clinical development stops. Method-of-use claims are more vulnerable to validity and infringement challenges, particularly when the indication and dosing regimen overlap with prior art.

Patent-strength assessment

Factor Assessment
Composition protection Potentially meaningful if unexpired and claim scope is narrow enough to cover the candidate
Formulation protection Likely secondary because the product is an oral small molecule
Method-of-use protection Potentially vulnerable to prior-art and obviousness attacks
Manufacturing protection Useful as a barrier to process replication, but rarely sufficient alone
Orange Book leverage None without approval
Litigation leverage Low at present because there is no commercial launch
Partnering value Dependent on clinical reactivation and remaining patent term

What market could PF-05221304 address?

The MASH market has substantial patient volume but is difficult to monetize because diagnosis rates are low, fibrosis staging is expensive, and treatment may require long-term monitoring. The approval of resmetirom created an initial commercial market, but it also established a safety and efficacy benchmark.

A successful PF-05221304 launch would likely require:

  • Demonstrated fibrosis improvement.
  • A favorable lipid profile or reliable statin combination.
  • An oral regimen with simple dosing.
  • Competitive pricing against resmetirom and future incretin-based treatments.
  • Use in patients with obesity, diabetes, or dyslipidemia.
  • Evidence of benefit in combination with GLP-1 or other MASH therapies.

Scenario-based revenue outlook

Scenario Development assumption Commercial result
Base case Pfizer does not restart the program No product revenue
Reactivation case Partner or Pfizer conducts a new Phase 2 study Limited value before pivotal proof
Approval case Positive fibrosis data and manageable dyslipidemia Potential niche or combination product
Best case Oral ACC inhibitor with superior lipid control and combination efficacy Multi-billion-dollar category opportunity, but low probability for PF-05221304 specifically

The base-case revenue forecast is zero because no launch program or regulatory filing is publicly established. A multi-billion-dollar MASH market forecast applies to the therapeutic category, not to PF-05221304. Resmetirom’s approval validates commercial demand, but it does not validate PF-05221304’s probability of reaching market.

What generic launch risks exist for PF-05221304?

There is no immediate generic launch risk because PF-05221304 is not approved and has no reference listed drug. If development resumes and the product is approved, the principal risks would arise from:

  • Paragraph IV challenges to composition patents.
  • Method-of-use challenges based on MASH prior art.
  • Generic development of alternative salts, polymorphs, or formulations.
  • Patent-term expiry before broad market penetration.
  • Off-label competition from approved metabolic drugs.

Unlike biologics, PF-05221304 would not face a biosimilar pathway. It would face conventional generic-drug competition under an ANDA pathway after relevant patent and regulatory exclusivity periods expire.

How does PF-05221304 compare with resmetirom?

Resmetirom has a decisive regulatory advantage because it is approved for noncirrhotic MASH with moderate-to-advanced fibrosis. PF-05221304 has a mechanistic advantage as a direct inhibitor of hepatic fatty-acid synthesis, but it lacks late-stage evidence and approval.

Issue PF-05221304 Resmetirom
FDA status Investigational Approved
Mechanism ACC inhibition THR-beta agonism
Liver-fat reduction Demonstrated in clinical studies Demonstrated
Fibrosis approval None Yes
Lipid concern Triglyceride and LDL increases associated with class Lipid effects are part of clinical profile
Patent position No Orange Book listing Approved-product patent estate
Commercial readiness Low Established
Generic risk Not currently applicable Future ANDA and patent challenges possible

Key Takeaways

  • PF-05221304 is an oral Pfizer ACC inhibitor developed for NASH/MASH.
  • Clinical studies demonstrated liver-fat reduction, supporting proof of mechanism.
  • The program did not produce a public FDA filing or approval.
  • Triglyceride and LDL increases are the principal class-related development concern.
  • PF-05221304 has no Orange Book listing, FDA exclusivity period, or identified Paragraph IV litigation.
  • The patent estate may include composition, method-of-use, formulation, and manufacturing claims, but confirmed expiry dates are not established by the drug code alone.
  • Resmetirom’s 2024 approval materially raises the evidence standard for any PF-05221304 restart.
  • The base-case commercial forecast is zero revenue unless Pfizer or a partner reactivates the program.
  • The compound could retain strategic value as a combination therapy if it demonstrates fibrosis benefit and improved lipid management.

FAQs

Is PF-05221304 the same drug as resmetirom?

No. PF-05221304 is an ACC inhibitor. Resmetirom is a thyroid hormone receptor beta agonist and is FDA-approved for MASH with moderate-to-advanced fibrosis.

Was PF-05221304 discontinued?

Public disclosures do not identify PF-05221304 as an active Pfizer commercial or late-stage program. Its publicly visible development has declined after Phase 2 work.

Does PF-05221304 have a generic version?

No. PF-05221304 is not approved, and no generic product can be substituted for it.

Could PF-05221304 be combined with a statin?

Yes. Lipid-lowering combination treatment was clinically relevant because ACC inhibition can increase triglycerides and LDL cholesterol. A statin combination could be part of any future development strategy.

Is PF-05221304 relevant to obesity-drug investors?

Potentially, but only as a discontinued or inactive MASH asset unless development resumes. Its investment value depends on reactivation, remaining patent life, and evidence that ACC inhibition improves fibrosis without unacceptable lipid effects.

References

  1. ClinicalTrials.gov. (n.d.). Study of PF-05221304 in participants with nonalcoholic steatohepatitis. U.S. National Library of Medicine. https://clinicaltrials.gov/
  2. U.S. Food and Drug Administration. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
  3. Pfizer Inc. (2023). Annual report and pipeline disclosures. https://www.pfizer.com/investors/financial-reports
  4. Younossi, Z. M., et al. (2021). Global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 74(2), 1014-1029.
  5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.